We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: MASLD
MedXY News
EnglishTag

MASLD

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Combination Therapy with GLP-1 Receptor Agonists and SGLT-2 Inhibitors Reduces Liver and Cardiovascular Risks in MASLD and Type 2 Diabetes
Diabetes & EndocrinologyGLP-1 receptor agonistMASLD

Combination Therapy with GLP-1 Receptor Agonists and SGLT-2 Inhibitors Reduces Liver and Cardiovascular Risks in MASLD and Type 2 Diabetes

By MedXY|Apr 25, 2026

A study reveals that combining GLP-1 receptor agonists with SGLT-2 inhibitors significantly lowers the risk of major adverse liver and cardiovascular outcomes in patients with MASLD and type 2 diabetes compared to monotherapy.

Validating the Virtual Biopsy: Noninvasive Surrogate Endpoints for Disease Progression and Treatment Efficacy in MASH
Clinical Updatesliver fibrosisMASH
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

Validating the Virtual Biopsy: Noninvasive Surrogate Endpoints for Disease Progression and Treatment Efficacy in MASH

By MedXY|Apr 2, 2026

This review synthesizes the evolving landscape of noninvasive tests (NITs) in MASH, detailing their role as surrogate endpoints for adverse outcomes and therapeutic response based on recent clinical trials and meta-analyses.

Telemedicine-Delivered Nutritional Therapy Slashes Risk of Advanced Liver Disease in Patients with Metabolic Dysfunction
Diabetes & EndocrinologyCarbohydrate ReductionMASLD

Telemedicine-Delivered Nutritional Therapy Slashes Risk of Advanced Liver Disease in Patients with Metabolic Dysfunction

By MedXY|Mar 18, 2026

A large-scale retrospective study demonstrates that individualized carbohydrate reduction through remote care significantly reduces the incidence of MASH and advanced liver complications in patients with type 2 diabetes and obesity compared

Navigating the New Frontier of MASLD: An Updated Clinical Pathway for Liver Health
Diabetes & Endocrinologyclinical guidelinesHepatology

Navigating the New Frontier of MASLD: An Updated Clinical Pathway for Liver Health

By MedXY|Mar 13, 2026

This article summarizes the updated clinical care pathway for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), highlighting new diagnostic nomenclature, risk stratification tools, and the integration of the first FDA-approv

Nearly 40 Percent of Indian Adults Impacted by MASLD: New Evidence from the Phenome India Cohort
GastroenterologyHepatologyliver fibrosis

Nearly 40 Percent of Indian Adults Impacted by MASLD: New Evidence from the Phenome India Cohort

By MedXY|Feb 17, 2026

The Phenome India study identifies a 38.9% age-adjusted prevalence **Constructing the JSON Object** Now, I’m carefully constructing the JSON object, which needs to be a valid, parseable string. I’m focusing on incorporating the

Berberine Improves Lipid Profiles and Inflammation but Fails to Reduce Visceral and Liver Fat in MASLD
Diabetes & EndocrinologyBerberineChuyển hóa mỡ máu

Berberine Improves Lipid Profiles and Inflammation but Fails to Reduce Visceral and Liver Fat in MASLD

By MedXY|Jan 24, 2026

The BRAVO randomized clinical trial demonstrates that while 1 g/d of berberine significantly lowers LDL-C and hs-CRP in individuals with obesity and MASLD, it does not impact visceral adipose tissue area or liver fat content over a six-mont

Adherence to the Planetary Health Diet Index Significantly Lowers MASLD Risk: A Global and Individual-Level Analysis
GastroenterologyMASLDmetabolic health

Adherence to the Planetary Health Diet Index Significantly Lowers MASLD Risk: A Global and Individual-Level Analysis

By MedXY|Jan 11, 2026

A comprehensive study integrating global and individual data reveals that adherence to the Planetary Health Diet Index (PHDI) provides significant protection against metabolic dysfunction-associated steatotic liver disease (MASLD), highligh

The Double-Win Diet: How the Planetary Health Index Protects Your Liver and the Earth
GastroenterologyChế độ ăn uống vì sức khỏe hành tinhliver health

The Double-Win Diet: How the Planetary Health Index Protects Your Liver and the Earth

By MedXY|Jan 11, 2026

This article explores the groundbreaking link between the Planetary Health Diet Index (PHDI) and reduced risks of metabolic dysfunction-associated steatotic liver disease (MASLD), offering evidence-based insights for personal health and env

Healthy Nordic Diet vs. Anti-Lipogenic High-Fat Diet: Superior Cardiometabolic Outcomes in the NAFLDiet Trial
Diabetes & EndocrinologyMASLDtype 2 diabetes

Healthy Nordic Diet vs. Anti-Lipogenic High-Fat Diet: Superior Cardiometabolic Outcomes in the NAFLDiet Trial

By MedXY|Jan 11, 2026

The NAFLDiet trial reveals that while both anti-lipogenic LCPUFA and Healthy Nordic Diets reduce liver fat, the Nordic diet offers superior benefits for weight loss, glycemic control, and systemic inflammation in patients with type 2 diabet

SGLT2 Inhibitors Emerge as Superior Choice for Cardiovascular Protection in Patients with T2DM and MASLD
Diabetes & Endocrinologycardiovascular outcomesMASLD

SGLT2 Inhibitors Emerge as Superior Choice for Cardiovascular Protection in Patients with T2DM and MASLD

By MedXY|Jan 7, 2026

A nationwide target trial emulation reveals that SGLT2 inhibitors significantly reduce major adverse cardiovascular events and mortality compared to other oral antidiabetics in patients with concurrent T2DM and MASLD, with benefits partiall

Tỷ lệ mắc xơ gan ở các nhóm kinh tế và nhân khẩu học tại Thụy Điển: Một nghiên cứu quần thể dựa trên đăng ký và bối cảnh toàn cầu
newsALDMASLD

Tỷ lệ mắc xơ gan ở các nhóm kinh tế và nhân khẩu học tại Thụy Điển: Một nghiên cứu quần thể dựa trên đăng ký và bối cảnh toàn cầu

By MedXY|Nov 24, 2025

Bài đánh giá này tổng hợp các bằng chứng về sự gia tăng tỷ lệ mắc xơ gan ở Thụy Điển, nhấn mạnh sự chênh lệch kinh tế xã hội rõ rệt, đặc biệt là trong xơ gan liên quan đến bệnh gan do rượu (ALD) và bệnh gan mỡ liên quan đến rối loạn chuyển

Cirrhosis Incidence Across Socioeconomic and Demographic Groups in Sweden: A Register-Based Cohort Study and Its Global Context
Clinical UpdatesALDcirrhosis

Cirrhosis Incidence Across Socioeconomic and Demographic Groups in Sweden: A Register-Based Cohort Study and Its Global Context

By MedXY|Nov 24, 2025

This review synthesizes evidence on rising cirrhosis incidence in Sweden, highlighting marked socioeconomic disparities particularly in ALD- and MASLD-related cirrhosis, with broader implications across high-income countries for targeted pr

GLP‑1 Receptor Agonists Associated with Lower Fibrosis Progression in MASLD and T2DM: Target‑Trial Emulation of Real‑World Data
Diabetes & EndocrinologyGLP-1RAliver fibrosis

GLP‑1 Receptor Agonists Associated with Lower Fibrosis Progression in MASLD and T2DM: Target‑Trial Emulation of Real‑World Data

By MedXY|Nov 23, 2025

A target-trial emulation of 4,476 matched T2DM patients with early MASLD found GLP-1RA use was associated with a 25% lower hazard of progression to high-risk FIB‑4 versus DPP‑4i (HR 0.75); no difference was seen for hard liver outcomes.

SGLT2 Inhibitors Linked to Lower Fibrosis Progression than DPP‑4 Inhibitors in MASLD with T2DM: Target‑Trial Emulation of Real‑World Cohorts
Diabetes & Endocrinologyliver fibrosisMASLD

SGLT2 Inhibitors Linked to Lower Fibrosis Progression than DPP‑4 Inhibitors in MASLD with T2DM: Target‑Trial Emulation of Real‑World Cohorts

By MedXY|Nov 17, 2025

A multicenter target‑trial emulation found SGLT2 inhibitor initiation was associated with a 22% lower risk of progression to advanced fibrosis (confirmed FIB‑4 >2.67) versus DPP‑4 inhibitors in adults with MASLD and T2DM and low‑to‑inter

Pemvidutide Produces Rapid Reductions in Liver Fat and AI‑Quantified Fibrosis in Early Phase Trials — Promise and Unanswered Questions
Diabetes & Endocrinologyliver fibrosisMASH

Pemvidutide Produces Rapid Reductions in Liver Fat and AI‑Quantified Fibrosis in Early Phase Trials — Promise and Unanswered Questions

By MedXY|Nov 14, 2025

Pemvidutide, a dual GLP‑1/glucagon receptor agonist, reduced liver fat markedly and produced small but statistically significant reductions in AI‑quantified fibrosis over 24 weeks in phase 2 studies, but longer trials with clinical endpoint

Phosphatidylethanol Reveals Substantial Underestimation of Alcohol Intake in Patients at Risk of Steatotic Liver Disease
GastroenterologyMASLDphosphatidylethanol

Phosphatidylethanol Reveals Substantial Underestimation of Alcohol Intake in Patients at Risk of Steatotic Liver Disease

By MedXY|Nov 9, 2025

A large prospective cohort shows phosphatidylethanol (PEth) correlates with self-reported alcohol intake but identifies frequent under-reporting; adding PEth to diagnostic pathways could improve subclassification of steatotic liver disease

Lean MASLD Is Not Benign: Higher Liver Events and Mortality in Normal-BMI Patients Across Three Large Cohorts
GastroenterologyMASLDMortality

Lean MASLD Is Not Benign: Higher Liver Events and Mortality in Normal-BMI Patients Across Three Large Cohorts

By MedXY|Nov 7, 2025

A pooled analysis of three population cohorts shows lean MASLD carries higher risks of liver-related events and all-cause and liver-related mortality despite lower cardiovascular event risk compared with non-lean MASLD.

Plant-Based Foods and Their Impact on Metabolic Health and Liver Function in Adults with MASLD and Comorbidities: A Systematic Review
Diabetes & Endocrinologyliver functionMASLD

Plant-Based Foods and Their Impact on Metabolic Health and Liver Function in Adults with MASLD and Comorbidities: A Systematic Review

By MedXY|Oct 28, 2025

This systematic review evaluates the effects of specific plant-based foods on metabolic and hepatic outcomes in adults with MASLD and related comorbidities. Findings reveal selective benefits of plant-based dietary components on liver healt

Time-Restricted Eating as a Promising Approach for Metabolic Dysfunction-Associated Steatotic Liver Disease: Evidence from a Randomized Controlled Trial
Diabetes & Endocrinologycalorie restrictionhepatic steatosis

Time-Restricted Eating as a Promising Approach for Metabolic Dysfunction-Associated Steatotic Liver Disease: Evidence from a Randomized Controlled Trial

By MedXY|Oct 28, 2025

A 16-week RCT demonstrates that time-restricted eating significantly reduces hepatic steatosis in MASLD, offering comparable metabolic benefits to calorie restriction without adverse events.

Hypertension as a Key Driver of Liver Fibrosis Progression and Adverse Outcomes in MASLD: Evidence from Large Cohorts
Cardiologyclinical outcomesHypertension

Hypertension as a Key Driver of Liver Fibrosis Progression and Adverse Outcomes in MASLD: Evidence from Large Cohorts

By MedXY|Oct 28, 2025

Hypertension independently worsens clinical outcomes and liver fibrosis progression in MASLD, highlighting the need for integrated cardiovascular and hepatic care.

Prev
2 / 3
123
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities